Although betaglycan (TGF-b type III receptor) is known to enhance TGF-b ligand binding to its type II receptor in murine lung epithelial cell lines, the biological significance of this phenomenon in the process of lung organogenesis is not understood. Betaglycan gene expression was detected in embryonic murine lungs undergoing branching morphogenesis in ex vivo culture. Antisense betaglycan oligodeoxynucleotides (ODN) resulted in up to 56% stimulation of lung branching morphogenesis in culture, while betaglycan mRNA and protein expression levels were suppressed by 90 and 82%, respectively. Following abrogation of betaglycan expression with antisense oligodeoxynucleotide, embryonic lungs were relatively insensitive to TGF-b: TGF-b2 (0.5 ng/ml) and TGF-b1 (20 ng/ml), respectively, down-regulated lung morphogenesis by 38 and 34% in control cultures, whereas TGF-b-induced inhibition was attenuated to 13 and 26% respectively, in the presence of betaglycan antisense oligodeoxynucleotides. TGF-b neutralizing antibodies also prevented TGF-b-mediated inhibition of lung branching in culture, supporting the speculation that autocrine/paracrine TGF-b signaling is minimal in the absence of betaglycan. Betaglycan was immunolocalized mainly to the epithelial cells in developing airways, a spatial distribution which overlaps with that of TGF-b type II receptor. Furthermore, abrogation of endogenous betaglycan gene expression prevented the characteristic downregulation of cyclin A and surfactant protein C (SP-C) mRNAs by exogenous TGF-b ligands. These results show that betaglycan expression is essential for optimal TGF-b signaling during embryonic lung development. We therefore conclude that the abrogation of endogenous betaglycan attenuates endogenous autocrine and/or paracrine TGF-b-mediated negative regulation of lung organogenesis.
Introduction
The embryonic lung originates as paired ventral outgrowths from the primitive foregut endoderm at E9.5 in the mouse, which progressively invades the surrounding mesenchyme through dichotomous branching. The branching morphogenesis pattern is established during the pseudoglandular stage of early lung development, while fetal branching morphogenesis in later stages results in the formation of sacs and alveoli along the distal-most branches of the bronchial tree (reviewed by Hilfer, 1996) . Embryonic lung development takes place within a complex milieu of regulatory factors, which may affect many parameters of cell behavior including cell proliferation, differentiation, migration and survival (Gurdon, 1987; Sporn and Roberts, 1990) . As lung morphogenesis develops, the endodermally-derived lung-epithelial rudiment continues to evaginate into mesodermally-derived mesenchyme. A complex series of epithelial-mesenchymal interactions instruct epithelial branching morphogenesis and cytodifferentiation of the pulmonary epithelium (Spooner and Wesells, 1970; Slavkin et al., 1984; Hilfer et al., 1985; Brody and Williams, 1992; Shannon, 1994) .
Transforming growth factor b (TGF-b) belongs to a superfamily including activin, bone morphogenetic proteins (BMP), Müllerian inhibiting substance and TGF-b1, 2 and 3. TGF-b family members are multifunctional polypeptides that regulate cell growth, differentiation and tissue morphogenesis through autocrine/paracrine signaling mechanisms. TGF-b induces growth arrest in various cell types including lung epithelial cells, and expression of a wide array of proteins, some of which are deposited in the lung extracellular matrix (recently reviewed in Derynck and Feng, 1997; Hoodless and Wrana, 1998) . TGF-bs elicit their effects by binding primarily to three cell surface receptor proteins termed TGF-b type I, type II, and type III receptors. Upon binding to TGF-b isoforms, TGF-b type III receptor (also called betaglycan) presents TGF-b directly to the TGF-b type II receptor, a serine/threonine kinase subunit (Wang et al., 1991; López-Casillas et al., 1991 . The TGFb type II receptor kinase trans-phosphorylates the type I receptor following TGF-b type I/type II receptor heteromerization, which in turn displaces betaglycan from TGF-b ligand binding Roberts et al., 1990) . The TGF-b type I/type II receptor complex subsequently trans-phosphorylates intracellular Smad proteins, and so eventually results in the propagation of a phosphorylation signal into the nucleus (Wrana et al., 1994; Derynck and Zhang, 1996; Lagna et al., 1996; Heldin et al., 1997) .
Betaglycan is a proteoglycan of 280-330 kDa and in many cell types is the most abundant TGF-b binding protein at the cell surface, at levels up to 200 000 molecules/cell (Massagué, 1985; Massagué and Like, 1985; Cheifetz et al., 1988; Segarini et al., 1989; López-Casillas et al., 1991) . Betaglycan is extensively modified with N-linked carbohydrates, heparan and chondroitin sulfate glycosaminoglycans although the core polypeptide has a size of 100-110 kDa (Andres et al., 1989; López-Casillas et al., 1994) . The cDNA-encoded polypeptide sequence of betaglycan is 853 amino acids in length including a large extracellular segment, a transmembrane region and a relatively short cytoplasmic domain of 41 amino acid residues. While the betaglycan ectodomain is capable of TGF-b ligand binding and contains glycosylation sites, no consensus signaling motif has been identified in its cytoplasmic tail (Wang et al., 1991; López-Casillas et al., 1991 .
In contrast to the intrinsically low affinity of TGF-b type II receptor to ligand, betaglycan binds to all three TGF-b isoforms with relatively high affinity (K d ranges from 30 to 300 pM), and the binding of TGF-b is conferred by the betaglycan polypeptide backbone and does not require the side chains (Cheifetz et al., 1987 (Cheifetz et al., , 1988 Cheifetz and Massagué, 1989; Segarini et al., 1987; Segarini and Seyedin, 1988; Andres et al., 1991; López-Casillas et al., 1994) . While betaglycan lacks signaling capacity and does not function directly in the TGF-b signaling pathway, the membrane-anchored betaglycan potentiates binding of TGF-b ligands to the signaling type II and type I receptors and, therefore is involved in ligand presentation. TGF-bs, particularly TGF-b2, have only a very low affinity for the TGF-b type II receptor, yet a high affinity for betaglycan. Coexpression of betaglycan with the TGF-b type II receptor confers an enhanced affinity of the latter receptor type for TGFb, which results in a considerably increased TGF-b binding to the type II receptor (López-Casillas et al., 1993) . Expression of betaglycan in cells that lack betaglycan significantly increased TGF-b binding to the TGF-b type II receptor and restored TGF-b activity (Wang et al., 1991; López-Casillas et al., 1993; Chen et al., 1997) . In the presence of TGF-b ligands, betaglycan forms a transient heteromeric complex with the TGF-b type II receptor, suggesting that the basis for the increase in TGF-b binding to the TGF-b type II receptor is due to the physical association of betaglycan with the type II receptor (López-Casillas et al., 1993; Moustakas et al., 1993) .
Although betaglycan is an important determinant of cell access to TGF-b, the biological significance of the betaglycan expression during embryonic lung development has not been defined. TGF-b signaling has been shown to negatively regulate lung development. We and others have previously determined that the signaling components of TGF-b pathway including TGF-b ligands, TGF-b type II receptor and Smad proteins, are involved in the regulation of both endogenous and exogenous TGF-b signaling on embryonic lung morphogenesis (Serra et al., 1994; Zhao et al., 1996 Zhao et al., , 1998a . In the present study, the role of betaglycan during early lung development was elucidated using an ex vivo embryonic lung culture undergoing extensive branching morphogenesis, in which a constant level of betaglycan expression was detected during the culture period. While the high affinity of betaglycan for TGF-b isoforms suggests a function as a reservoir for readily available TGF-b that can be presented with high affinity to the TGF-b type II receptors, we postulated that betaglycan expression modulates lung development through regulation of TGF-b ligand accessibility to the TGF-b signaling pathway. To test this hypothesis, we utilized an antisense oligodeoxynucleotide (ODN) to abrogate endogenous betaglycan gene expression as a loss-of-function strategy during embryonic lung growth in culture. We show that both the TGF-b-mediated inhibition of lung branching morphogenesis and the TGF-binduced anti-proliferative effect are significantly attenuated when endogenous betaglycan gene expression is abolished. Therefore, the observed refractoriness to both endogenous and exogenous TGF-b ligands in the absence of betaglycan gene expression indicates that betaglycan is indispensable for optimal autocrine/paracrine TGF-b signaling during lung organogenesis.
Results

Betaglycan is expressed throughout embryonic mouse lung culture period
While both TGF-b type II and type I receptors are known to be expressed during the process of embryonic and fetal lung development (Zhao and Young, 1995; Zhao et al., 1996) , the temporal expression pattern of betaglycan during embryonic lung development has not been described. We thus started the current study by characterizing the developmental expression of betaglycan mRNA during embryonic mouse lung-branching morphogenesis in culture (Fig. 1) .
To evaluate the temporal expression of betaglycan gene in cultured embryonic lung, a highly sensitive and accurate assay to measure murine betaglycan mRNA amount was developed based on competitive RT-PCR methodology. A same pair of PCR primers were designed and used for amplification of both betaglycan cDNA and betaglycan competitor ( Fig. 2A) , as described in 'Section 4'. When a constant amount of betaglycan competitor was used to coamplify with a 1:2 dilutional series of betaglycan cDNA, an electrophoretic pattern showing an inverse relationship in band intensities between betaglycan cDNA and its competitor was obtained (Fig. 2B) . Therefore, the ratio of betaglycan cDNA to betaglycan competitor PCR products reflected the initial amounts of betaglycan cDNA and betaglycan competitor included in the betaglycan competitive PCR amplification. Following densitometric analysis, a regression line (R 2 Ͼ 0.95) for betaglycan competitive PCR was obtained by plotting a logarithm of band intensities of betaglycan cDNA over its competitor against the initial amounts . When a constant amount of betaglycan competitor (100 fg) was used to co-amplify with a 1:2 serial dilution of betaglycan cDNA (6.25-1600 fg), an inverse relationship in PCR product intensities was obtained after electrophoresis (B). A linear correlation (C, A) was derived from electrophoretic pattern with high coefficient factor (R 2 >0.95), while a similar line with identical slope was obtained when different amounts of reverse-transcribed total RNA was used (B). BG, betaglycan.
of betaglycan cDNA added in the betaglycan competitive PCR (Fig. 2C, A) .
In the next step, different amounts of reverse-transcribed total RNA from cultured embryonic lungs were used to coamplify with a same amount of betaglycan competitor, and a similar regression line (R 2 Ͼ 0.95) with same slope value was obtained (Fig. 2C, B) . The above same slope values indicated that recombinant betaglycan behaved identically to the betaglycan cDNA derived from reverse-transcribled products. Thus, it is feasible to accurately measure betaglycan mRNA levels as its cDNA equivalent, using the linear equation derived from recombinant betaglycan standards. The detection limit for betaglycan competitive RT-PCR is 6.25 fg betaglycan cDNA or 6.25 ng reverse-transcribed total RNA (Fig. 2C) .
E11.5 embryonic murine lungs were cultured for up to 4 days in BGJb media. Cultured lungs were extracted for total RNA, reverse transcribed and subjected to betaglycan competitive PCR assay for endogenous betaglycan mRNA quantification (Fig. 1) . Betaglycan mRNA was persistently expressed in embryonic lungs throughout the culture period ( Fig. 1A ) and significant changes in murine betaglycan mRNA expression were not observed (Fig. 1B) . Therefore, during the embryonic lung explant culture stage where active pulmonary branching morphogenesis occurs, betaglycan mRNA is persistently expressed at relatively constant levels, in addition to the presence of TGF-b type II and type I receptor mRNAs.
Antisense ODN to betaglycan stimulates embryonic mouse lung branching morphogenesis in culture
While endogenous TGF-b signaling is known to inhibit embryonic lung morphogenesis, the function of betaglycan during the process is unclear. Since betaglycan gene expression takes place during early lung branching morphogenesis in culture, the resultant biological impact on embryonic lung development was examined in a loss-of-function experiment. We devised an antisense oligodeoxynucleotide (ODN) strategy to achieve effective inhibition of betaglycan gene expression during lung morphogenesis. Antisense ODN to betaglycan, when added exogenously to the lung culture media, stimulated embryonic lung branching morphogenesis in a concentration-dependent manner at both 20 and 40 mM concentrations (Fig. 3b,d,f) . However, either scrambled ( Fig. 3c ,e) or sense (not shown) control ODN at above doses did not show any phenotypic effect on lung branching morphogenesis in parallel cultures. Quantification of peripheral branches revealed that antisense ODN to betaglycan increased embryonic lung branching by significant 37 or 56% at 20 or 40 mM ODN, respectively (P Ͻ 0.05), whereas both scrambled control ODN (115 or 101% of media control at 20 or 40 mM, respectively) and sense control ODN to betaglycan (112 or 92% of media control at 20 or 40 mM, respectively) did not change lung branching morphogenesis in comparison to media controls (Fig. 4) .
Inhibition of endogenous betaglycan gene expression by betaglycan antisense ODN in lung culture
Inhibition of endogenous betaglycan gene expression using antisense ODN to betaglycan in lung explant culture was confirmed by quantification of mouse betaglycan mRNA levels in cultured lung. Competitive RT-PCR assays were used to measure the endogenous amounts of betaglycan mRNA in lung cultured with media control, scrambled, sense control or antisense ODN to betaglycan. As shown in competitive PCR electrophoretic patterns in Fig. 5A , Fig. 3 . Embryonic murine lung branching morphogenesis in culture. E11.5 (a) mouse lungs underwent extensive morphogenesis to develop into a characteristic branching pattern after 4 days in culture in a chemicallydefined, serum-free media (b). A dose-dependent stimulation of branching morphogenesis was observed in lungs cultured with 20 (d) and 40 mM (f) antisense ODN complementary to betaglycan mRNA, in comparison to scrambled ODN controls (c and e for 20 and 40 mM, respectively). While the addition of TGF-b2 (g) inhibited lung branching in the presence of betaglycan scrambled ODN, such an TGF-b-mediated inhibition was minimized when betaglycan antisense ODN was used instead (h). Magnification: a, 40 × ; b-h, 25 × . embryonic lungs cultured in both 20 and 40 mM doses of scrambled and sense control ODNs to betaglycan yielded amounts of betaglycan mRNA comparable to media control. In contrast, lungs treated with antisense ODN to betaglycan demonstrated decreased amounts of endogenous betaglycan mRNA, indicating that only betaglycan antisense ODN, not scrambled or sense control ODN, efficiently inhibited endogenous betaglycan gene expression. Due to the linearity of the betaglycan competitive PCR standard curve (Fig. 2) , amounts of betaglycan mRNA in various samples were visually compared based on the electrophoretic pattern ( Fig. 5A ), while accurate measurements were also obtained through densitometric analysis and subsequent calculation (Fig. 5B) . Antisense ODN to betaglycan inhibited endogenous betaglycan mRNA levels in a concentration-dependent fashion: 20 mM betaglycan antisense ODN reduced endogenous betaglycan level to 42%, and 40 mM to 10% of basal level (P Ͻ 0.05). However, none of the control ODN (scrambled and sense) to betaglycan at either of the above doses significantly altered endogenous betaglycan mRNA amounts in lungs in culture.
Betaglycan is known to present TGF-b ligands to the TGF-b type II receptor. The type II receptor thus forms a hetero-complex with TGF-b type I receptor. To confirm that betaglycan antisense ODN specifically inhibits mouse betaglycan mRNA expression, but not the related TGF-b type II nor type I receptor gene expression, both endogenous TGFb type II and type I receptor mRNA levels were quantified in the lung cultured treated with betaglycan ODNs. Although Fig. 4 . Antisense ODN to betaglycan up-regulates lung branching morphogenesis in a concentration-dependent manner in culture. As determined by the number of peripheral branches, betaglycan antisense ODN (20 and 40 mM) stimulated embryonic lung branching morphogenesis in culture in a dose-dependent fashion, while both scrambled and sense control ODNs did not change lung branching relative to media control. The number of terminal branches in lungs in media control was arbitrarily set as 100%. The lung branch number was expressed as the mean ± SD of at least ten lung explants for each assayed condition. MC, media control; SR, scrambled ODN; SE, sense ODN; AS, antisense ODN. . Inhibition of betaglycan mRNA levels using antisense ODN to betaglycan in lung culture. (A) Antisense ODN complementary to murine betaglycan mRNA displayed a dose-dependent (20 and 40 mM) inhibition on endogenous betaglycan mRNA amounts in embryonic lung explants in culture, as shown by electrophoretic pattern of betaglycan competitive PCR, while both scrambled and sense ODNs at above concentrations did not change mouse lung betaglycan mRNA levels in culture. While betaglycan antisense ODN efficiently decreased endogenous betaglycan mRNA expression in cultured lungs, it did not adversely affect endogenous mRNA expression of both TGF-b type II and type I receptors in lungs in culture. (B) Betaglycan mRNA levels in betaglycan ODN-treated lungs after b-actin normalization using media control as 100%. Betaglycan antisense ODN reduced endogenous betaglycan mRNA levels in a dosedependent fashion relative to media control, while either betaglycan scramble or sense ODN did not significantly alter the endogenous betaglycan mRNA amounts in cultured embryonic murine lungs. Experiments were performed with at least three lung explant samples under each assayed condition and at least repeated for three times with reproducible results obtained, although only single lung sample in each treatment was shown in electrophoretic patterns in (A). Each bar in (B) represents the mean ± SD.
antisense ODN to betaglycan efficiently attenuated betaglycan mRNA expression in embryonic lungs in culture, endogenous TGF-b type II or type I receptor mRNA level were not adversely affected by antisense ODN to betaglycan, as shown in TGF-b type II and type I receptor competitive PCR assays (Fig. 5A) . Therefore, antisense ODN to betaglycan only inhibited betaglycan gene expression with both high efficiency and specificity in lung explant culture. The observed stimulation of embryonic lung branching morphogenesis could thus be attributed to the abrogation of endogenous betaglycan, but not TGF-b type II and type I receptor gene expression in culture.
Western analysis was also used to confirm the reduction of betaglycan protein levels with betaglycan antisense ODN. The extensive modification of the betaglycan core protein with glycosylation caused betaglycan to migrate heterogeneously in the range of 280-330 kDa (Fig. 6A) . Cultured lungs treated with 40 mM betaglycan antisense ODN showed decreased levels of betaglycan protein in comparison to lungs with scrambled, sense ODN (not shown), or media control treatment at the same concentration. After densitometric analysis of Western blot, endogenous betaglycan protein amount was decreased to only 18% (P Ͻ 0.05) of media control with betaglycan antisense ODN treatment at 40 mM, while either scrambled or sense betaglycan control ODN at the same dose did not show any inhibitory effect on endogenous betaglycan protein levels in lung culture (Fig. 6B) . Thus, only the antisense betaglycan ODN, not the scrambled or the sense betaglycan control ODN, resulted in a significant inhibition of endogenous betaglycan expression at both transcriptional and translational levels.
Abrogation of endogenous betaglycan attenuates TGFb-mediated lung branching inhibition
Inhibition of endogenous betaglycan gene expression using antisense betaglycan ODN results in positive regulation of embryonic lung morphogenesis. This suggests that endogenous TGF-b signaling is reduced when betaglycan gene expression is abolished. Thus, the role of betaglycan was further studied in the response to exogenously-added TGF-b ligands. It is known that exogenous TGF-b ligands negatively regulate lung branching morphogenesis when added to the culture media. Since betaglycan increases the affinity of TGF-b ligands to the TGF-b type II receptor, we tested the hypothesis that exogenous TGF-b-induced inhibition on lung branching morphogenesis would be attenuated when endogenous betaglycan gene expression is abrogated.
Exogenously-added TGF-b2 ligand is known to inhibit the lung branching morphogenesis in culture in a concentration-dependent manner: 0.5 ng/ml TGF-b2 decreased lung branching by up to 38% (P Ͻ 0.05) in the presence of 40 mM scrambled control ODN to betaglycan (Fig. 7, left  panel) . A similar TGF-b2 dose-response inhibition was also obtained in media control lungs or in lungs treated with 40 mM sense control ODN to betaglycan (data not shown). However, when 40 mM antisense ODN to betaglycan was added to culture media to inhibit endogenous betaglycan gene expression in embryonic lungs, an attenuation of TGF-b2-mediated inhibition on lung branching was observed. While TGF-b2 still down-regulated embryonic lung branching in a concentration-dependent manner when betaglycan gene expression was abrogated in the lung culture, the level of inhibition of branching decreased at each tested TGF-b2 concentration (0.01, 0.05, 0.1, and 0.5 ng/ ml): 0.5 ng/ml TGF-b2 only inhibited lung branching by 13% (P Ͻ 0.05), in comparison to 38% lung branching inhibition of the same dose TGF-b2 in the presence of normal betaglycan expression (lung images shown in Fig.  3g,h) . Thus, abrogation of betaglycan gene expression attenuated lung branching morphogenesis inhibition in culture in response to exogenous TGF-b2 by 57-72% at doses of 0.01, 0.05, 0.1, and 0.5 ng/ml. The refractoriness to TGF-bmediated lung branching inhibition in the absence of betaglycan suggests the speculation that affinity of TGF-b2 ligand for the TGF-b type II receptor was reduced in the absence of betaglycan. Therefore, membrane-bound betaglycan expression is indispensable for efficient TGF-b2 signaling in embryonic lungs in culture.
The autocrine/paracrine activity of TGF-b1 on lung morphogenesis was also examined in the absence of betaglycan (Fig. 7b, right panel) . Abrogation of endogenous betaglycan gene expression caused a 23-40% attenuation on TGF-b1-induced lung branching inhibition in culture at a TGF-b1 concentration range of 2.5 to 20 ng/ml. Thus, similar to TGF-b2, TGF-b1-induced lung-branching inhibition was also partially reversed in the absence of endogenous betaglycan gene expression in culture. Thus, we speculate that betaglycan increases both TGF-b2 and to a lesser extent TGF-b1 binding to the TGF-b type II receptor, and consequently the TGF-b type I receptor during embryonic lung development.
Betaglycan protein is primarily localized to airway epithelium
We have previously used immunocytochemistry to localize TGF-b type II receptor protein primarily to the developing airways in lungs in culture (Zhao et al., 1996) . We therefore compared betaglycan spatial localization during embryonic lung development. A betaglycan polyclonal goat IgG antibody was used to detect the mouse betaglycan protein in cultured embryonic lungs using immunohistochemistry (Fig. 8) . Betaglycan protein was mainly localized to the developing airways in cultured lung sections, in both proximal (Fig. 8, A1 ) and peripheral (A2) airway epithelial cells. Thus, it appears that both betaglycan and TGF-b type II receptor proteins co-localize in the airway epithelium in cultured murine embryonic lung. However, in cultured lungs treated with antisense ODN to betaglycan, a reduced betaglycan immunoreactivity intensity was observed in both proximal (B1) and distal (B2) epithelium, corresponding to the Western analysis that antisense ODN to betaglycan effectively inhibited betaglycan protein expression.
TGF-b neutralizing antibodies also reverses TGF-binduced inhibitory effects on lung branching morphogenesis
As an alternative approach to whether the observed insensitivity to TGF-b-mediated lung branching inhibition is attributed to decreased TGF-b ligand activity when betaglycan gene expression is abolished, a TGF-b neutralizing antibody was added to lung explant culture media. As shown above, TGF-b2-induced inhibition of lung branching morphogenesis was prevented when betaglycan gene expression was abrogated using 40 mM betaglycan antisense ODN (Fig.  9a) . A similar reversal of TGF-b2-induced lung-branching inhibition was observed when 5 mg/ml TGF-b2 neutralizing antibody was added in the presence of TGF-b2. Similarly, TGF-b1 neutralizing antibodies also prevented the TGF-b1-induced inhibition of lung branching morphogenesis in culture (Fig. 9, right panel) . The TGF-b neutralizing antibodies efficiently bind and inactivate TGF-b ligands. Our observation that both abrogation of betaglycan expression and TGFb neutralizing antibody approaches resulted in partial release of TGF-b-induced inhibition of lung branching suggests that the effects of decreased autocrine/paracrine TGF- b signaling are identical to the effects of abrogation of endogenous betaglycan gene expression.
Down-regulation of both cyclin A and SP-C mRNA levels by TGF-b is prevented when endogenous betaglycan expression is abrogated in cultured lungs
TGF-b-induced growth arrest occurs late in G 1 phase and is accompanied by a decrease in the steady-state level of cyclin A protein in mammalian cells. Our data suggests that the observed stimulation of embryonic lung branching in the absence of endogenous betaglycan in lung culture is due to a lack of betaglycan-regulated responsiveness to TGF-b signaling. Therefore, we used cyclin A as a marker gene to evaluate the rate of cellular proliferation during embryonic lung development. We have previously shown that exogenously-added TGF-b ligand decreased mRNA levels of cyclin A during embryonic lung morphogenesis (Zhao et al., 1996) . In the present study, exogenous TGF-b2 (0.5 ng/ml) was found to exert an inhibitory effect on cyclin A mRNA expression not only when added alone (not shown) but also in the presence of 40 mM scrambled ODN to betaglycan, as shown in the electrophoretic pattern of cyclin A competitive PCR (Fig. 10) . However, in the presence of antisense ODN to betaglycan, neither TGF-b2 nor TGFb1 significantly decreased cyclin A levels. The finding that exogenous TGF-b ligands failed to down-regulate cyclin A gene expression in the absence of betaglycan indicates that the TGF-b-mediated growth inhibitory signaling is attenuated without betaglycan present. Therefore, betaglycan is required for activation of anti-proliferative TGF-b signaling during embryonic lung development.
Surfactant protein C (SP-C) expression was also examined to evaluate the function of betaglycan gene expression during embryonic lung development. When added to culture media, TGF-b2 or TGF-b1 reduced epithelial SP-C gene expression in media control lungs as well as in lungs treated with betaglycan scrambled ODN, as measured by competitive PCR quantification of lung SP-C mRNA levels (Fig.  10) . However, exogenous TGF-b2 or TGF-b1 no longer inhibited epithelial SP-C mRNA expression when betaglycan gene expression was abrogated.
Discussion
Although the role of signaling molecules including TGFb type I and type II receptors, and Smads 2, 3 and 4 have been the focus of studies to elucidate the functional importance of TGF-b signaling during embryonic lung branching morphogenesis, relatively little attention has been paid to the role of betaglycan. Therefore, this is the first report to demonstrate that endogenous betaglycan expression is essential for optimal levels of TGF-b signaling during lung development, establishing a functional connection between TGF-b type III and type II receptors. We have also shown that TGF-b-induced negative regulation of both lung branching and proliferation can be reversed or significantly attenuated through abrogation of endogenous betaglycan gene expression using an antisense oligodeoxynucleotide (ODN) inhibitory strategy. It therefore appears that betaglycan gene expression is important for optimal TGF-b signaling during embryonic lung morphogenesis. Fig. 9 . Effect of TGF-b neutralizing antibody on embryonic lung branching morphogenesis. While either TGF-b2 (a, left panel) or TGF-b1 (b, right panel) inhibited lung branching in culture in the presence of scrambled control ODN to betaglycan, such TGF-b-induced lung branching inhibitions were not seen when betaglycan antisense ODN was used in the lung culture. A similar reversal on the TGF-b-mediated inhibition of lung branching morphogenesis was also observed when TGF-b neutralizing antibody was added to the lung culture media. Data is shown as mean ± SD. b2, TGF-b2; b1, TGF-b1; Ab, neutralizing antibody. Fig. 10 . Cyclin A and SP-C mRNA levels in cultured embryonic murine lungs. Exogenously-added TGF-b2 reduced both cyclin A and SP-C mRNA expression in embryonic lungs in culture in the presence of scrambled control ODN to betaglycan, as shown by electrophoretic patterns of respective cyclin A and SP-C competitive PCR. However, in lung explants cultured with antisense ODN to betaglycan, both cyclin A and SP-C mRNA levels were not decreased by exogenous TGF-b2. The experiments were repeated with reproducible outcomes at least four times, although only one typical result is shown.
Betaglycan and the TGF-b type II receptor can be coimmunoprecipitated when bound to TGF-b, suggesting that TGF-b binding to the type II receptor results from a physical association of betaglycan with the type II receptor (López-Casillas et al., 1993; Moustakas et al., 1993) . In a number of cell lines, over-expression of betaglycan increases affinity labeling of both TGF-b type I and type II receptors by [ 125 I]TGF-b (López-Casillas et al., 1993; Hall et al., 1996; Chen et al., 1997; Sun and Chen, 1997) . This is particularly striking in the case of TGF-b2 which has only minimal affinity for the TGF-b type II receptor, yet a high affinity for betaglycan. Additionally, coexpression of betaglycan with TGF-b type II receptor also to a lesser extent increases the binding activity of TGF-b1. It is therefore conceivable that normal betaglycan expression is necessary to support the formation of TGF-b-ligand-type II receptor complexes, while TGF-b signaling may be attenuated without betaglycan.
Candidate inductive peptide growth factors for pulmonary morphogenesis include EGF, bFGF, HGF, KGF, and PDGF, all of which exert inductive or permissive influences on lung development as demonstrated by gain and/or loss of function experiments either in early embryonic mouse lung organ culture, in transgenic mice, or in null mutant mice (Raaberg et al., 1991 (Raaberg et al., , 1995 Warburton, 1991; Warburton et al., 1992; Peters et al., 1994; Miettinen et al., 1995 Miettinen et al., , 1997 Souza et al., 1995; Bonström et al., 1996; Ohmichi et al., 1998) . However, both addition of exogenous TGF-bs to embryonic mouse lungs in culture and organ specific overexpression of TGF-b1 in transgenic mice bearing a chimeric SP-C promoter-directed TGF-b1 expression construct, result in hypoplastic phenotypes (Serra et al., 1994; Serra and Moses, 1995; Zhao et al., 1996 Zhao et al., , 1998a , indicating that exogenous TGF-b exerts a negative regulatory influence on lung morphogenesis. Furthermore, blockade of endogenous TGF-b signaling using antisense ODN to either TGF-b type II receptor or Smad2 and 3 or 4 proteins resulted in stimulation of lung branching morphogenesis, suggesting that endogenous TGF-b signaling also negatively regulates lung development (Zhao et al., 1996 (Zhao et al., , 1998a . Thus, TGFb receptor signaling negatively modulates and therefore presumably balances the positive functions of signaling by other cognate peptide growth factor receptor pathways during the process of embryonic lung branching morphogenesis.
Betaglycan 'gain-of-function' has been investigated previously using betaglycan gene over-expression strategies in cell lines that lack endogenous betaglycan gene expression. Expression of exogenous betaglycan not only enhances the TGF-b ligand binding to the TGF-b type II receptor, but also restores the autocrine/paracrine activity of TGF-b in recipient cells (López-Casillas et al., 1993; Chen et al., 1997) . Relatively high and persistent levels of expression of endogenous betaglycan gene were found during lung branching morphogenesis in culture, in comparison to levels of expression of both TGF-b type I and type II receptors. Based on the above observation, we explored the biological function of endogenous betaglycan during lung organogenesis using an antisense ODN inhibitory 'loss-of-function' approach. We have shown that the antisense ODN to betaglycan used in the present study efficiently and specifically inhibited endogenous betaglycan gene expression in culture: endogenous betaglycan mRNA and protein levels were reduced by 90 and 82% only in the presence of antisense, not either scrambled or sense betaglycan ODN, while TGFb type I and type II receptor gene expression were not adversely affected.
While betaglycan increases TGF-b binding to the signaling receptors of TGF-b pathway, betaglycan over-expression does not show enhanced TGF-b responsiveness in cells with low levels of either TGF-b type II or type I receptor expression (López-Casillas et al., 1993; Sun et al., 1994) . Apparently, betaglycan alone is not sufficient to support TGF-b binding onto the cell surface. It appears that both TGF-b type II and type I receptor are necessary for the betaglycan-induced increased responsiveness to TGF-b ligands.
Our immunohistochemical result that the spatial distribution of both betaglycan and TGF-b type II receptor overlap supports the hypothesis that betaglycan presents TGF-b ligand to type II receptor through physical association during lung morphogenesis. While embryonic lungs in culture were relatively insensitive to either exogenous TGF-b2 or TGF-b1 in the absence of betaglycan, our data also shows that abrogation of betaglycan expression resulted in greater attenuation of TGF-b2 ligand-induced inhibition of lung branching than for TGF-b1. This differential attenuation of effects for specific TGF-b isoforms correlates with the finding in both normal and transformed cell lines that betaglycan enhances TGF-b2, and to a lesser extent, TGF-b1 binding to the type II receptor (López-Casillas et al., 1993; Sankar et al., 1995) . Thus, the present results support the speculation that the betaglycan acts as a direct regulator of TGF-b ligand access to the TGF-b signaling kinase receptors during early lung development.
Betaglycan gene expression is also responsible for transducing TGF-b-mediated anti-proliferative effects and for the negative regulation of surfactant protein gene expression by TGF-b. TGF-b has been characterized to exert its inhibitory effect on cell growth by inducing cell G 1 -S phase arrest. Inhibition of cyclin A synthesis prevents mammalian fibroblasts from entering S phase (Girard et al., 1991) . TGFb1-induced growth arrest occurs late in G 1 phase and is accompanied by a decrease in the steady-state level of cyclin A protein and alterations in the behavior of cdc2 and cdk2 kinases (Laiho et al., 1990; Resnitzky et al., 1992) . TGF-b down-regulates cyclin A gene expression in lung culture (Zhao et al., 1996 (Zhao et al., , 1998b . However, cyclin A mRNA level is refractory to TGF-b-mediated inhibition without betaglycan gene expression, indicating that the presence of betaglycan is necessary for TGF-b-mediated cellgrowth inhibition during lung development. Likewise, reversal of pulmonary epithelium-specific SP-C gene expression by TGF-b in the absence of betaglycan supports the conclusion that betaglycan is needed for the maintenance of TGF-b-mediated negative regulation on SP-C gene expression.
The TGF-b neutralizing antibodies were used herein to decrease the effective concentration of TGF-b ligand and subsequent TGF-b activity in both cell and organ cultures. The use of TGF-b neutralizing antibody in lung culture media efficiently blocks the exogenous TGF-b added to the lung culture, resulting in reduction of TGF-b signaling activity. While TGF-b inhibits lung branching morphogenesis in culture, addition of TGF-b neutralizing antibody resulted in a reversal of TGF-b-induced lung branching inhibition similar to that seen following the abrogation of betaglycan gene expression. Our observation that both betaglycan abrogation and TGF-b neutralizing antibody prevented TGF-b-mediated inhibition of lung growth and branching further support the notion that abrogation of betaglycan expression results in decreased responsiveness to TGF-b during early lung development.
Betaglycan is structurally related to endoglin, a membrane glycoprotein binding to TGF-bs. Betaglycan and endoglin share considerable sequence similarity except in their extracellular domains (Cheifetz et al., 1992) . The antisense ODN to betaglycan used herein was thus strategically designed to target the betaglycan N-terminal sequence where betaglycan has least sequence homology to endoglin. Using competitive RT-PCR, we demonstrated that betaglycan antisense ODN did not affect endogenous endoglin gene expression level while endogenous betaglycan gene expression was efficiently inhibited in the betaglycan antisense ODN-treated lung culture (data not shown). The other two TGF-b-binding proteoglycans, decorin and biglycan, were also shown to have unchanged gene expression levels regardless of the presence of betaglycan antisense ODN in lung explant in culture. Therefore, the observed effect on lung branching morphogenesis and pulmonary gene expression in the current study is due exclusively to the loss of endogenous betaglycan in lungs in culture, but not to endoglin, decorin, or biglycan.
In addition to membrane-bound betaglycan, the secreted form of betaglycan has been suggested to exist in extracellular matrices. Soluble betaglycan is secreted by limited proteolytic cleavage of the membrane-anchored form and release of the betaglycan ectodomain (Andres et al., 1989; López-Casillas et al., 1991) . However, based on our betaglycan immunohistochemistry and microscopic examination that betaglycan primarily localizes to cellular membranes in cultured lungs, we suggest that membranebound betaglycan is the major functional form during embryonic lung development in culture. Nevertheless, the presence of soluble betaglycan in some cell types may suggest a yet to be determined function for soluble betaglycan. It may be important to determine whether soluble betaglycan can also function as a competitor with membrane-bound betaglycan for TGF-b binding onto cell surface receptors, in a manner analogous to decorin and biglycan (Yamaguchi et al., 1990) .
In conclusion, the present study reveals betaglycan to function as a necessary modulator of TGF-b access to its cognate signaling receptor kinases during embryonic lung development. Expression of endogenous betaglycan during lung morphogenesis is therefore essential for controlling the optimal level of TGF-b signaling in the negative regulation of cellular growth, epithelial-specific gene expression, and lung branching. The ability of betaglycan to affect directly TGF-b interaction with the signaling receptors suggests a mechanism by which betaglycan modulates normal lung organogenesis.
Materials and methods
Animals and tissues
Timed pregnant Swiss-Webster female mice were obtained from Simonsen Laboratories. Mice were mated and checked for vaginal plugs on the same day so that the variation in gestational age was Ͼ6 h. Embryos from embryonic day 11.5 (E11.5, 6-7 mm in length with approximate 45 somites) were used (day of plug is defined as E0). Embryos were dissected in sterile Hank's buffer and the lungs were removed by micro-dissection and placed into organ culture.
Embryonic lung culture
Early mouse embryonic lungs (E11.5) were cultured under serum-free, chemically defined conditions as reported previously (Warburton et al., 1992; Zhao et al., 1998b) . E11.5 lung explants were placed on 0.80 mm MF-Millipore filters supported by stainless steel grids in Grobstein culture dishes and cultured in BGJb medium (Gibco, Grand Island, NY) supplemented with 0.1 mg/ml ascorbic acid and 50 units/ml penicillin/streptomycin. About 1 ml medium was added to each dish (ten explants/dish) to establish an airfluid interface at the level of the explants. Betaglycan oligodeoxynucleotides (ODN), TGF-b ligands, and/or TGF-b neutralizing antibodies (R & D Systems, Minneapolis, MN) were added exogenously to lung culture media to desirable concentrations. The cultures were maintained in 100% humidity with an atmosphere of 95% air and 5% CO 2 for 4 days. The media were changed every 2 days.
Quantification of terminal branches
Since branching morphogenesis per se is the key bioassay read-out of the biological effects for testing the role of betaglycan during embryonic lung development, three independent measurements of branching morphogenesis were devised: (i) the number of airway generations from the tra-chea to the most distal branch of the longest visible airway; (ii) the number of air sacs visible around the periphery of the lung explants; (iii) and computerized pattern recognition analysis of the number of individual terminal respiratory units in the whole explant. These analyses were performed on whole-mounts of lung explants using transillumination to visualize structures, photomicroscopy to record permanent image, and on paraffin-embedded sections of fixed tissue.
Betaglycan antisense oligodeoxynucleotide inhibition
Betaglycan antisense ODN 5′-CCAGCAGCCAGTCTC-TC-3′ (to the N-terminal domain) was designed to inhibit betaglycan gene expression in embryonic lung explant culture (López-Casillas et al., 1991) . Two same-length control ODNs to betaglycan were also devised: (i) 5′-AGCCT-CAGCTCCACTCG-3′ (same nucleotide composition but scrambled sequence) and (ii) 5′-GAGAGACTGGCT-GCTGG-3′ (sense sequence). The first three and the last three bases in each ODN sequence were modified by phosphorothioation to improve ODN stability against nuclease degradation in organ culture. The ODNs were synthesized and subsequently purified by HPLC (USC Microchemical Core Lab, Los Angeles, CA). Antisense, scrambled, or sense ODNs were added exogenously to early mouse embryonic lung culture to achieve final concentration of 20 or 40 mM.
RNA extraction and reverse transcription
Total RNA from cultured lung explant was extracted by guanidinium thiocyanate following homogenization as we described previously . Extracted total RNA was immediately incubated at 37°C for 1 h in 20 ml of 10 mM Tris (pH 8.4), 50 mM KCl, 2 mM MgCl 2 , 1 mM dithiothreitol, 5 units ribonuclease inhibitor, 0.5 mM dNTP, 100 pmol oligo-d(T) [12] [13] [14] [15] [16] [17] [18] , and 200 units of M-MLV reverse transcriptase (USB, Cleveland, OH). The reverse transcriptase reaction was terminated by heating for 5 min at 95°C (Zhao et al., 1996) . The resultant cDNA products were used for competitive PCR assays.
Competitive PCR assay
Establishment of competitive PCR methodology for specific mRNA quantification of pulmonary genes has been described elsewhere . Briefly, a set of primers (primers 1 and 2, Fig. 2A ) were designed for murine betaglycan to amplify a cDNA fragment of 244 bp in size. Two composite primers were synthesized for betaglycan competitor construction ( Fig. 2A) : each composite primer had the target betaglycan primer sequence (black box) incorporated into a stretch of sequence (hatched box), designed to hybridize to the opposite strand of a heterologous DNA fragment. The desired primer sequences (primers 1 and 2) were thus engineered into a competitor cDNA following PCR amplification, ensuring that both betaglycan cDNA and its competitor utilize the same set of primers in the betaglycan competitive PCR. The betaglycan competitor was 345 bp in length. Both betaglycan and its competitor PCR products were DNA sequenced to confirm their identities (Sanger et al., 1977) . Competitive PCR assays for TGF-b type II, type I receptor, cyclin A, and SP-C were developed in similar manners as that for betaglycan.
PCR amplification was carried out in a Robocycler (Stratagene, La Jolla, CA) using a modification of a previously described assay for TGF-b type II receptor (Zhao et al., 1998b) . There were 35 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 2 min and extension at 72°C for 2 min were routinely performed after an initial 3-min denaturation at 94°C. The final cycle included a 5-min extension step. The reaction mixture contained 10 mM Tris (pH 9.4), 50 mM KCl, 2 mM MgCl 2 (optimized), 0.01% gelatin, 0.1% Triton X-100, 20 pmol primer sets, 100 mM dNTP and 0.5 unit Advantage Klentech DNA polymerase (Clontech, Palo Alto, CA). Reaction mixture containing a known amount of competitor was added to reverse-transcribed samples derived from 50 ng total RNA or to dilutions of standard cDNA templates in a total volume of 50 ml. Concentrations of cDNA standard solutions were determined spectrophotometrically upon absorbance at 260 nm using 1 A 260 = 50 mg/ ml. b-actin competitive PCR as an internal control was performed on the same samples. As a negative control for genomic DNA, un-reverse-transcribed total RNA was also included in the competitive PCR assays.
Western analysis
Embryonic lung explants were harvested after culture and placed in a SDS lysis buffer containing protease inhibitors. The total protein concentration in each lung sample was determined using the Micro BCA Protein Assay Reagent Kit (Pierce, Rockland, IL). Equal amounts of total protein (60 mg) from each sample was loaded in each well on a 7.5% Tris-Glycine polyacrylamide gel. The electrophoresis was undertaken in a Modular Mini-PROTEAN II Electrophoresis System (Bio-Rad, Hercules, CA). Protein on the gel was then transferred to a Millipore Immobilon-P membrane by using a Bio-Rad Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, Hercules, CA). Equal transfer efficiency for each sample was confirmed by Coomassie Blue stain of the membrane after Western blot. The subsequent Western blot was performed utilizing Chemiluminescence Western Blotting Kit (Boehringer Mannheim, Indianapolis, IN). A final concentration of 0.5 mg/ml betaglycan antibody (goat polyclonal IgG, R and D Systems, Minneapolis, MN) was incubated with membrane at 4°C overnight. POD (horseradish peroxidase)-labeled secondary antibody was added to incubate with membrane for 2 h. The chemiluminescent light was then captured by Kodak X-Omat AR film for a permanent record.
Immunocytochemistry
Cultured lung explants were fixed with 4% paraformaldehyde upon harvest and embedded into paraffin. Embryonic lung sections (5 mm thick) on HistoGrip-coated slides were prepared for immunohistochemical study. Betaglycan antibody (extracellular domain-specific goat polyclonal IgG, R and D Systems, Minneapolis, MN) was used at a concentration of 20 mg/ml for betaglycan protein immunostaining. Biotinylated second antibody and streptavidin-peroxidase conjugate were used to detect bound antibody. Subsequent addition of aminoethyl carbazole chromogen (AEC) generated a reddish precipitate surrounding the betaglycan antigen (Zymed, South San Francisco, CA). Three negative controls were run in parallel with betaglycan antibody to ensure specificity: (1) normal goat serum; (2) bovine serum albumin; (3) water control.
Densitometric and statistical analysis
Electrophoresis following PCR amplification was performed on 3% agarose gels (3:1 mixture of Nusieve and Seakem, FMC, Rockland, ME) in a submarine gel unit (C.B.S. Scientific, Del Mar, CA), where target and competitor PCR products were separated by size. DNA bands were visualized by staining with 5 mg/ml ethidium bromide. Images were both photographed by Polaroid 667 films for permanent record and captured by a computerized scanner for intensity measurement. The intensity was determined by densitometric analysis in pixels using ImageQuan bandanalyzing software (Molecular Dynamics, Sunnyvale, CA). Calculation and statistical analysis were performed using Microsoft Excel 5.0.
Every experiment was repeated at least three times, with reproducible results. Standard deviation (SD) was derived from about ten individual lung explants for each assayed condition. A P Ͻ 0.05 (evaluated by t-test) was accepted as statistically significant.
